Clinical experience with antithrombotic drugs acting on purine receptor pathways

Drug Development Research

Volumn 52, Issue 1-2, 2001, Pages 202-212

  Storey, Robert F ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Adenosine diphosphate; Antiplatelet drugs; Blood platelets; P2 receptors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARC 69931MX; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; TICLOPIDINE; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PATHOGENESIS; STEADY STATE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOGENESIS; THROMBOSIS;

EID: 0035041424     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.1117     Document Type: Conference Paper

References (2)

1. Antiplatelet Trialists' Collaboration. 1994. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106.
2. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G, the Studio della Ticlopidina nell'Angina Instabile Group. 1990. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 82:17-26.